Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 3Carcinoma, Hepatocellular 3Colorectal Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Hypertension, Portal 1Gallbladder Neoplasms 1Fibrosis 1Colonic Neoplasms 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Pentoxifylline 3Tocopherols 2tremelimumab 1ruxolitinib 1maltodextrin 1durvalumab 1atezolizumab 1Vitamin E 1Sunitinib 1Standard of Care 1Specimen Handling 1Simvastatin 1Pravastatin 1Physical Therapy Modalities 1Pharmaceutical Preparations 1Magnetic Resonance Spectroscopy 1Losartan 1Liver Transplantation 1Ketoprofen 1Hyperbaric Oxygenation 1Bevacizumab 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fibrosis × Liver Transplantation × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡